Genezen appoints Chief Commercial Officer to Executive Leadership Team

Genezen, a US-based cell and gene therapy Contract Development and Manufacturing Organization (CDMO) specializing in lentiviral and retroviral vector manufacturing, continues to scale and expand its commercial operations with the appointment of Jeff Whitmore as Chief Commercial Officer (CCO).

With a career in biotechnology spanning over 25 years, Whitmore joins Genezen from mRNA Therapeutic CDMO, TriLink BioTechnologies, part of Maravai LifeSciences, where he most recently served as Vice President of Commercial Operations and had responsibility for commercial expansion and strategy (During his time at TriLink, he helped guide the firm through a rapid increase in demand for mRNA production during the peak of the COVID-19 pandemic). Prior to this, he held leadership positions at biostability technology company, Biomatrica, and immunodiagnostics maker, Singulex.

Looking to bolster the buildout of Genezen’s commercial presence, Whitmore will maximize growth opportunities at the organization’s recently expanded viral vector process development and cGMP production facility​ in Fishers, Indiana (US).